Akern consolidates relations with China
Akern®‘s partnership with the Chinese company EnterNutr Guangzhou New Health Biotechnology Co., Ltd., a Guangzhou-based company founded in 2008 by Dr. Hanxi Li, started in 2019. Today EnterNutr is a company supported by governmental funds and well-established in the hospital setting in providing supplements and devices for parenteral nutrition therapy.
In 2022 Akern® obtained NMPA certification authorizing the sales of its medical devices in the clinical market.
This month Akern®‘s CSO visited 8 well-known Chinese hospitals (including: 301 Concordia Hospital Beijing, Beijing National Hospital, Shenzhen Municipal Hospital, South Medical University Shenzhen Hospital, South Medical University Zhujiang Hospital) to initiate scientific collaborations and share ideas for research project in intensive care and oncology and geriatrics departments.
2024 publications update:
- Xie, Hailun, et al. “Association of systemic inflammation with the obesity paradox in cancer: results from multi-cohort studies.” Inflammation Research (2023): 1-10.
- Wu, Ting-Ting, et al. “Resistance training combined with β-hydroxy β-methylbutyrate for patients with critical illness: A four-arm, mixed-methods, feasibility randomised controlled trial.” Intensive and Critical Care Nursing 82 (2024): 103616.
- Wu, Ting-Ting, et al. “Effects of a multilevel intervention of resistance training with or without beta-hydroxy-beta-methylbutyrate in medical ICU patients during entire hospitalisation: a four-arm multicentre randomised controlled trial.” Critical Care 27.1 (2023): 493.
- Cai, Bin, et al. “Influence of body composition assessment with bioelectrical impedance vector analysis in cancer patients undergoing surgery.” Frontiers in Oncology 13 (2023).
